Skip to main content
. 2013 Apr 11;4(3):213–218. doi: 10.1136/flgastro-2013-100325

Figure 1.

Figure 1

Recommendations for stopping Dabigatran and Rivaroxaban prior to low-risk and high-risk endoscopic procedures.